TipRanks
The coronavirus pandemic crisis shows no signs of abating, even with a vaccine coming on to the markets. Were still facing severe social lockdown policies, with a number of states (such as California, Minnesota, and Michigan) forcing even harsher restrictions on this round than previously.Its a heavy blow for the leisure industry that is still reeling from one of the most difficult years in memory. The difficulties faced by restaurants are getting more press, but for the cruise industry, corona has been a perfect storm.Prior to the pandemic, the cruise industry which had been doing $150 billion worth of business annually was expected to carry 32 million passengers in 2020. Thats all gone now. During the summer, the industry reeled when over 3,000 COVID cases were linked to 123 separate cruise ships, and resulted in 34 deaths. After such a difficult year, its useful to step back and take a snapshot of the industrys condition. JPMorgan analyst Brandt Montour has done just that, in a comprehensive review of the cruise industry generally and three cruise line giants in particular."We believe cruise shares can continue to grind higher in the near term, driven overwhelmingly by the broader vaccine backdrop/progress. Looking out further, operators will face plenty of headwinds when restarting/ramping operations in 2Q3Q21, but significant sequential improvement of revenues/cash flows over that period will likely dominate the narrative, and we believe investors will continue to look through short-term setbacks to a 2022 characterized by fully ramped capacity, near-full occupancies, and so far manageable pricing pressure," Montour opined.Against this backdrop, Montour has picked out two stocks that are worth the risk, and one that investors should avoid for now. Using TipRanks Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these cruise line players.Royal Caribbean (RCL)The second-largest cruise line, Royal Caribbean, remains a top pick for Montour and his firm. The company has put its resources into facing and meeting the pandemics challenges, shoring up liquidity and both streamlining and modernizing the fleet.Maintaining liquidity has been the most pressing issue. While the company has resumed some cruising, and has even taken delivery of a new ship, the Silver Moon, most operations remain suspended. For Q3, the company reported adjusted earnings of -$5.62, below consensus of -$5.17. Management estimates the cash burn to be between $250 million and $290 million monthly. To combat that, RCL reported having $3.7 billion in liquidity at the end of September. That included $3 billion in cash on hand along with $700 million available through a credit facility. Total liquidity at the end of Q3 was down more than 9% from the end of Q2. Since the third quarter ended, RCL has added over $1 billion to its cash position, through an issue of $500 million senior notes and a sale of stock, putting an additional 8.33 million shares on the market at $60 each.In his note on Royal Caribbean, Montour writes, [We] are most constructive on OW-rated RCL, which we believe has the most compelling set of demand drivers... its extensive investments in premium priced new hardware, as well as consumer data, all set RCL up well to outgrow the industry in revenue metrics, margins, and ROIC over the longer term.Montour backs his Overweight (i.e. Buy) rating with a $91 price target. This figure represents a 30% upside potential for 2021. (To watch Montours track record, click here)Is the rest of the Street in agreement? As it turns out, the analyst consensus is more of a mixed bag. 4 Buy ratings and 6 Holds give RCL a Moderate Buy status. Meanwhile, the stock is selling for $69.58 per share, slightly above the $68.22 average price target. (See RCL stock analysis on TipRanks)Norwegian Cruise Line (NCLH)With a market cap of $7.45 billion and a fleet of 28 ships, Norwegian Cruise Line found its relatively smaller size as an advantage in this pandemic time. With a smaller and newer fleet, overhead costs, especially ship maintenance, were lower. These advantages dont mean that the company has avoided the storm. Earlier this month, Norwegian announced a prolongation of its suspension of voyages policy, covering all scheduled voyages from January 1, 2021 through February 28, 2021, plus selected voyages in March 2021. These cancellations come as Norwegians revenues are down in the third quarter, the top line was just $6.5 million, compared to $1.9 billion in the year-ago quarter. The company also reported a cash burn of $150 million per month.To combat the cash burn and minimal revenues, Norwegian, in November and December, took steps to improve liquidity. The company closed on $850 million in senior notes, at 5.875% and due in 2026, during November, and earlier this month closed an offering of common stock. The stock offering totaled 40 million shares at $20.80 per share. Together, the two offerings raised over $1.6 billion in new capital.On a more positive note, Norwegian is preparing for an eventual resumption of full services. The company announced, on Dec 7, a partnership with AtmosAir Solutions for the installation of air purification systems on all 28 vessels of its current fleet, using filtration technology known to defeat the coronavirus.JPMs Montour points out these advantages in his review of Norwegian, and sums up the bottom line: This coupled with a relatively newer, higher-end, brand/ship footprint would generally lead us to believe it was in a good position to outperform on pricing growth, though its demographics skewing to older age customers probably will remain a drag through 2021. Ultimately, NCLH is a high-quality asset within the broader cruise industry, with a higher beta to a cruise recovery, and it should see outperformance as the industry returns and investors look further out the risk spectrum.Montour gives the stock a $30 price target and an Overweight (i.e. Buy) rating. His target implies an upside of 27% on the one-year time frame.Norwegian is another cruise line with a Moderate Buy from the analyst consensus. This rating is based on 4 Buys, 4 Holds, and 1 Sell set in recent months. Like RCL above, the stock price here, $23.55, is currently higher than the average price target, $23.22. (See NCLH stock analysis on TipRanks)Carnival Corporation (CCL)Last up, Carnival, is the worlds largest cruise line, with a market cap of $23.25 billion, more than 100 ships across its brands, and over 700 destination ports. In normal times, this giant footprint gave the company an advantage; now, however, it has become an expensive liability. This is clear from the companys fiscal Q3 cash burn, which approached $770 million.Like the other big cruise companies, Carnival has extended its voyage cancellations, or, in the companys terms, the pause in operations. The Cunard line, one of Carnivals brands, has cancelled voyages on the Queen Mary 2 and the Queen Elizabeth through early June of next year. Carnival has also cancelled operations in February from the ports of Miami, Galveston, and Port Canaveral, and pushed back the inaugural voyage of the new ship Mardi Gras to the end of April 2021. These measures were taken in compliance with coronavirus restrictions.Carnivals shares and revenues are suffering deep losses this year. The stock is down 60% year-to-date, despite some recent price rallies since the end of October. Revenues fell to just $31 million in the fiscal third quarter, reported in September. Carnival reported a loss of nearly $3 billion in that quarter. The company did end the third quarter with over $8 billion in available cash, an impressive resource to face the difficult situation.This combination of strength and weakness led Montour to put a Neutral (i.e. Hold) rating on CCL shares. However, his $25 price target suggests a possible upside of 23%.In comments on Carnival, Montour wrote, [We] believe that some of the same relative net yield drags it saw in 2018-2019 due to its sheer size will likely become top of mind on the other side of this crisis However, given CCLs relative share discount, less pricing growth ahead of the crisis, and geographical diversification, we see it as the company with the least downside over the next few months and are not surprised by its recent outperformance. We believe this will reverse in the 2H21. Overall, Carnival has a Hold rating from the analyst consensus. This rating is based on 10 reviews, breaking down to 1 Buy, 8 Holds, and 1 Sell. The stock is selling for $20.28 and its $18.86 average price target implies a downside potential of ~7%. (See CCL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Here is the original post:
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock? - Yahoo Finance
- U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033 - BioSpace - April 16th, 2024
- 6 biotechnology universities in the USA developing young talent - Labiotech.eu - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - NBC Right Now - April 16th, 2024
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewswire - April 16th, 2024
- Lee Hsien Loong presided over efforts to retool Singapore's export-driven economy by focusing on advanced ... - pdclarion.com - April 16th, 2024
- BIO's top lobbyist heads out the door - FiercePharma - April 16th, 2024
- BIO's top lobbyist exits, signaling reorganization - STAT - STAT - April 16th, 2024
- Biotech Rebound Could Boost This ETF - ETF Trends - April 16th, 2024
- US National Security, China and Biotechnology in 2024 - BioSpace - April 8th, 2024
- How to Invest in Biotechnology (Updated 2024) - Nasdaq - April 8th, 2024
- Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression - Nature.com - April 8th, 2024
- Genetically encoding colors and images into bioengineered microbial materials - Nature.com - April 8th, 2024
- Ambition and urgency: Biotechnology and Biomanufacturing in the EU - EURACTIV - April 8th, 2024
- Scientists create plastic-free vegan leather that dyes itself, grown from bacteria - Phys.org - April 8th, 2024
- For national security, the U.S. must maintain its biotech dominance - STAT - April 8th, 2024
- LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside? - Yahoo Finance - April 8th, 2024
- Is biotechnology a good career? Here are the pros and cons - Labiotech.eu - March 18th, 2024
- Saving Biology With Blue Biotechnology - The Maritime Executive - March 18th, 2024
- 30 Biggest Biotechnology Companies in the World - Yahoo Finance - March 18th, 2024
- WuXi out of biotech trade group, U.S. and China relations to blame - STAT - March 18th, 2024
- Can Biotechnology Save the Fashion Industry? - EARTH.ORG - March 18th, 2024
- Huber high-precision temperature control solutions for the pharmaceutical industry and biotechnology - Labmate Online - March 18th, 2024
- The twelve hottest biotech companies in the Boston area - Labiotech.eu - March 18th, 2024
- Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off - The Globe and Mail - March 10th, 2024
- Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation - Simply Wall St - March 10th, 2024
- The Top 25 Biotechnology Companies of 2024 - The Healthcare Technology Report. - March 10th, 2024
- Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature ... - Nature.com - March 10th, 2024
- MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain ... - Business Wire - March 10th, 2024
- Global Pharmaceuticals and Biotechnology Distribution Deals Analysis Report and Directory 2024: Breakdown of ... - PR Newswire - March 10th, 2024
- Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of ... - PR Newswire - March 10th, 2024
- INTERNATIONAL BIOTECHNOLOGY TRUST has a healthy attitude towards paying investors - This is Money - March 10th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Biotechnology should be high on the agenda at the Munich Security Conference - The Hill - February 18th, 2024
- Boston is best in the world at biotech. Beijing wants to do it better - WBUR News - February 18th, 2024
- Multiomics Are The Next Step In Biotechnology - Securities.io - February 18th, 2024
- SPARKing academic technologies across the valley of death - Nature.com - February 18th, 2024
- Is Nurix Therapeutics Inc (NRIX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Addressing the Threat to U.S. Biotechnology: Concerns Over Genetic Data Security - Medriva - February 18th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- Is Tempest Therapeutics Inc (TPST) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Immunome Inc (IMNM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- Is Larimar Therapeutics Inc (LRMR) a Leader in the Biotechnology Industry? - InvestorsObserver - February 18th, 2024
- US lawmakers, visiting Cambridge, warn of a rising Chinese threat to US biotech - The Boston Globe - February 18th, 2024
- Should Biotechnology Stock Viking Therapeutics Inc (VKTX) Be in Your Portfolio Monday? - InvestorsObserver - February 18th, 2024
- How the push to limit Chinese biotech could threaten U.S. edge - Axios - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- BioAro Inc to Host Inaugural Longevity Innovation Forum in Dubai, UAE - Yahoo Finance - January 25th, 2024
- Is Akebia Therapeutics Inc (AKBA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - January 25th, 2024
- Agricultural Biotechnology Market Projected to Reach USD 64.7 billion, with Advancing CAGR of 9.5% by 2031 ... - Yahoo Finance - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- ZWI Therapeutics Announces Closing of $10M Series A Financing - FinSMEs - January 25th, 2024
- Breaking Barriers: Tiamat Sciences Shatters Norms with All-Female Executive Team - Yahoo Finance - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Is Cabaletta Bio Inc (CABA) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Why Investors and Media are Calling Biotech Showcase The Place to Be to Start the Year - Business Wire - January 25th, 2024
- Is IGC Pharma Inc (IGC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Is Summit Therapeutics Inc (SMMT) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Biotech Stocks: The Top 5 To Watch As Shares Trend Down - Investor's Business Daily - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- HRMY: Are These 3 Biotech Stocks Worth Buying? - StockNews.com - January 25th, 2024
- Global Preparative Chromatography Market is projected to reach US$ 2,139.4 Million by 2034 Amid Growing ... - Yahoo Finance - January 25th, 2024
- Is Immunome Inc (IMNM) a Leader in the Biotechnology Industry? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023